Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Radiosensitization by histone deacetylase inhibition in an osteosarcoma mouse model.
Blattmann C, Thiemann M, Stenzinger A, Christmann A, Roth E, Ehemann V, Debus J, Kulozik AE, Weichert W, Huber PE, Oertel S, Abdollahi A. Blattmann C, et al. Among authors: thiemann m. Strahlenther Onkol. 2013 Nov;189(11):957-66. doi: 10.1007/s00066-013-0372-8. Epub 2013 Jun 27. Strahlenther Onkol. 2013. PMID: 23801068
Establishment of a patient-derived orthotopic osteosarcoma mouse model.
Blattmann C, Thiemann M, Stenzinger A, Roth EK, Dittmar A, Witt H, Lehner B, Renker E, Jugold M, Eichwald V, Weichert W, Huber PE, Kulozik AE. Blattmann C, et al. Among authors: thiemann m. J Transl Med. 2015 Apr 30;13:136. doi: 10.1186/s12967-015-0497-x. J Transl Med. 2015. PMID: 25926029 Free PMC article.
Prexasertib (LY2606368) reduces clonogenic survival by inducing apoptosis in primary patient-derived osteosarcoma cells and synergizes with cisplatin and talazoparib.
Heidler CL, Roth EK, Thiemann M, Blattmann C, Perez RL, Huber PE, Kovac M, Amthor B, Neu-Yilik G, Kulozik AE. Heidler CL, et al. Among authors: thiemann m. Int J Cancer. 2020 Aug 15;147(4):1059-1070. doi: 10.1002/ijc.32814. Epub 2019 Dec 19. Int J Cancer. 2020. PMID: 31782150 Free PMC article.
High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group.
Schellong G, Pötter R, Brämswig J, Wagner W, Prott FJ, Dörffel W, Körholz D, Mann G, Rath B, Reiter A, Weissbach G, Riepenhausen M, Thiemann M, Schwarze EW. Schellong G, et al. Among authors: thiemann m. J Clin Oncol. 1999 Dec;17(12):3736-44. doi: 10.1200/JCO.1999.17.12.3736. J Clin Oncol. 1999. PMID: 10577845 Clinical Trial.
The CD40 agonist HERA-CD40L results in enhanced activation of antigen presenting cells, promoting an anti-tumor effect alone and in combination with radiotherapy.
Frankish J, Mukherjee D, Romano E, Billian-Frey K, Schröder M, Heinonen K, Merz C, Redondo Müller M, Gieffers C, Hill O, Thiemann M, Honeychurch J, Illidge T, Sykora J. Frankish J, et al. Among authors: thiemann m. Front Immunol. 2023 May 26;14:1160116. doi: 10.3389/fimmu.2023.1160116. eCollection 2023. Front Immunol. 2023. PMID: 37304285 Free PMC article.
43 results